INS and type 1 diabetes mellitus: Compared to multiple daily injections, continuous subcutaneous insulin infusion (CSII) is associated with lower glycated hemoglobin A1c (HbA1c) levels, fewer severe hypoglycemic episodes, and improved quality of life and treatment satisfaction in people with T1DM [9].